Angiotensin-II Blockade in Mitral Regurgitation

NCTId: NCT00014846

Summary

To compare two angiotensin-II blockade drug treatments for the treatment of organic mitral regurgitation.

Detailed Description

BACKGROUND:

Mitral regurgitation (MR) is frequent and its prevalence is increasing with aging of the population. Organic MR, due to primary valvular lesions has severe consequences determined by its degree, with left ventricular (LV) remodeling and dysfunction, left atrial (LA) enlargement, leading to poor clinical outcome. Surgery can eliminate MR, but carries notable risks and is not applicable to all patients. Therefore, chronically decreasing MR, protecting LV and LA with vasoactive treatment are major goals of medical therapy. However, effects of chronic oral vasoactive treatment of MR are controversial and uncertain and recent practice guidelines underscored these gaps in knowledge and did not recommend vasoactive treatment of MR. Hence, a trial of treatment of organic MR is needed.

DESIGN NARRATIVE:

A randomized clinical trial, placebo controlled, double-blind, without crossover, of one year oral treatment with potent tissue angiotensin blockade (with one arm using Candesartan [an angiotensin-II receptor antagonist] and one arm using Ramipril [a tissue angiotensin converting enzyme inhibitor] ) titrated to the maximally tolerated dose. The trial was preceded by an acute study to determine tolerance. End-points were measured by Doppler-Echocardiography for quantitation of MR (regurgitant volume) using a combination of three simultaneous methods (quantitative Doppler, two-dimensional echocardiography, proximal flow convergence) and combination of echocardiography and electron beam computed tomography for left ventricular and left atrial volume measurement. This single center study sought to enroll a total of 135 patients. The analysis was based on intention to treat and compared changes in regurgitant volume, left ventricular end-diastolic volume index and left atrial volume measured after one year of treatment with active drugs or placebo.

Eligibility

Eligibility Criteria

Gender Minimum Age Maximum Age Healthy Volunteers?
Both 21 Years 80 Years False

No eligibility criteria

Interventions & Outcomes

Study Interventions & Types

Drug Intervention(s)

Candesartan
Ramipril
Ramipril

Unfortunately, there is no location information available.
Please check back again later or Search for a different study

Related Keywords & Studies

Conditions and Diseases with Related Research Studies

  1. Heart Diseases
  2. Mitral Valve Insufficiency

Related Intervention Keywords

Related Heart Diseases Research

  1. A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators
  2. A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
  3. A Study of the Effect of Blinding in a Trial of Blood Filtration During Heart Surgery
  4. A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-Lung Bypass
  5. A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI
  6. Acute Cardiac Ischemia in Women in the ACI/TIPI Trial
  7. Adiposity and Fat Patterning in Black Americans
  8. AIDS-Associated Heart Disease -- Incidence and Etiology
  9. Anaesthetic Management of Women With Heart Disease For Labor and Delivery
  10. APPROPRIATE - Rate Adaptive Pacing Sensor